GoKawiilAlzheimer’s disease is widely depicted as a linear cascade from amyloid-β accumulation to Tau pathology and neurodegeneration. We propose instead that the disease unfolds through discrete molecular, cellular and network phases organized around biological inflection points. At these thresholds, stress-driven loss of homeostasis produces qualitative shifts in cellular behavior that alters disease progression. These altered states spread across local tissue-domains, accumulate as a mosaic across the brain, and progressively engage vulnerable centres of information processing that control cognitive performance. The induction of amyloid-associated Tau phosphorylation marks a pivotal inflection point, separating amyloid-dominated tissue states from domains in which neuronal Tau stress responses have emerged. This framework helps reconcile the dissociation between pathology and symptoms, clarifies the shared architecture of familial and sporadic disease and reframes Alzheimer’s disease as a disorder shaped by biological thresholds, timing, and progressive erosion of homeostatic resilience.
Inflection points and transitions in Alzheimer’s disease
Why This Matters
This article challenges the long-standing linear model of Alzheimer's progression, proposing instead a framework of biological inflection points and tissue-level thresholds. This matters because it could reshape how researchers design drug trials and biomarkers, potentially explaining why past amyloid-targeted therapies have shown limited clinical benefit despite reducing pathology.
Key Takeaways
- Alzheimer's may progress through discrete phase transitions rather than a simple linear cascade from amyloid to Tau to neurodegeneration.
- The shift from amyloid-dominated states to Tau stress responses is identified as a critical inflection point in disease progression.
- This model could help explain the mismatch between pathological burden and clinical symptoms, informing better treatment timing and strategy.
Get alerts for these topics